Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Genome Editing with Crispr-Cas9 Systems: Basic Research and Clinical Applications

The Indonesian Biomedical Journal · Vol. 9 No. 1 (2017) · hlm. 1–1

DOI
10.18585/inabj.v9i1.272
ISSN
2085-3297, 2355-9179
Terbit
2017-04-01
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Recently established genome editing technologies will open new avenues for biological research and development. Human genome editing is a powerful tool which offers great scientific and therapeutic potential.CONTENT: Genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated protein 9 (Cas9) technology is revolutionizing the gene function studies and possibly will give rise to an entirely new degree of therapeutics for a large range of diseases. Prompt advances in the CRISPR/Cas9 technology, as well as delivery modalities for gene therapy applications, are dismissing the barriers to the clinical translation of this technology. Many studies conducted showed promising results, but as current available technologies for evaluating off-target gene modification, several elements must be addressed to validate the safety of the CRISPR/Cas9 platform for clinical application, as the ethical implication as well.SUMMARY: The CRISPR/Cas9 system is a powerful genome editing technology with the potential to create a variety of novel therapeutics for a range of diseases, many of which are currently untreatable.KEYWORDS: genome editing, CRISPR-Cas, guideRNA, DSB, ZFNs, TALEN

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 145 tautan kepenulisan bersama · 70 lintas organisasi · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Padjadjaran University
  • PT Prodia StemCell Indonesia (Indonesia)
  • Universitas Trisakti
  • Udayana University
  • University of Indonesia
  • Universitas Airlangga
  • Organisasi lain
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Suryani As’ádHasanuddin University15
Gatot Susilo LawrenceHasanuddin University7
Ferry SandraUniversitas Trisakti7
Yani LinaHasanuddin University6
Ilhamjaya PatellongiHasanuddin University6
Irma Ruslina DefiPadjadjaran University6
Cynthia Retna SartikaPT Prodia StemCell Indonesia (Indonesia)5
Anwar SantosoUdayana University4
Syakib BakriHasanuddin University4
Melisa Intan BarlianaPadjadjaran University4
Keri LestariPadjadjaran University4
Teguh RanakusumaUniversity of Indonesia3
Irawan YusufHasanuddin University3
Rima HaifaPT Prodia StemCell Indonesia (Indonesia)3
Trilis YuliantiHasanuddin University3
Irma Rahayu LatarissaPadjadjaran University3
Ida Paulina SorminHasanuddin University3
Erizal SugionoHasanuddin University3
Keri Lestari DandanPadjadjaran University3
Lucia HerminawatiHasanuddin University3
Aziiz Mardanarian RosdiantoPadjadjaran University3
Rina TrianaPadjadjaran University3
Yenny SurjawanHasanuddin University2
Mansyur AriefHasanuddin University2
Andri HidayatHasanuddin University2
Ahmad FariedPadjadjaran University2
Marsetio DonosepoetroUniversitas Airlangga2
Burhanuddin BaharHasanuddin University2
Widjaja LukitoSEAMEO Regional Center for Food and Nutrition2
Indriyanti Rafi SukmawatiHasanuddin University2
Antonia Anna LukitoHasanuddin University2
Mansyur ArifHasanuddin University2
Anna MeilanaPadjadjaran University2
Made Putra SemadhiPadjadjaran University2
Candra NinghayuHasanuddin University1
Cissy Bana KartasasmitaPadjadjaran University1
Irmansyah IrmansyahNational Research and Innovation Agency1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Genome Editing with Crispr-Cas9 Systems: Basic Research and Clinical Applications</dc:title><dc:creator>Anna Meiliana</dc:creator><dc:creator>Nurrani Mustika Dewi</dc:creator><dc:creator>Andi Wijaya</dc:creator><dc:subject>CRISPR/Cas9</dc:subject><dc:subject>genome editing</dc:subject><dc:subject>gene therapy</dc:subject><dc:subject>off-target effects</dc:subject><dc:subject>guide RNA</dc:subject><dc:subject>DNA double-strand breaks</dc:subject><dc:subject>zinc finger nucleases</dc:subject><dc:subject>TALEN</dc:subject><dc:subject>clinical translation</dc:subject><dc:subject>gene delivery</dc:subject><dc:subject>ethics of gene editing</dc:subject><dc:subject>disease therapeutics</dc:subject><dc:description xml:lang="en">BACKGROUND: Recently established genome editing technologies will open new avenues for biological research and development. Human genome editing is a powerful tool which offers great scientific and therapeutic potential.CONTENT: Genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated protein 9 (Cas9) technology is revolutionizing the gene function studies and possibly will give rise to an entirely new degree of therapeutics for a large range of diseases. Prompt advances in the CRISPR/Cas9 technology, as well as delivery modalities for gene therapy applications, are dismissing the barriers to the clinical translation of this technology. Many studies conducted showed promising results, but as current available technologies for evaluating off-target gene modification, several elements must be addressed to validate the safety of the CRISPR/Cas9 platform for clinical application, as the ethical implication as well.SUMMARY: The CRISPR/Cas9 system is a powerful genome editing technology with the potential to create a variety of novel therapeutics for a range of diseases, many of which are currently untreatable.KEYWORDS: genome editing, CRISPR-Cas, guideRNA, DSB, ZFNs, TALEN</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2017-04-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v9i1.272</dc:identifier><dc:identifier>10.18585/inabj.v9i1.272</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 9 No 1 (2017); 1-1</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/272/346</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>